<DOC>
	<DOCNO>NCT01646736</DOCNO>
	<brief_summary>Evaluation clinical efficacy safety profile glucocorticosteroid combine oral T2 ( chloroform/methanol extract Tripterygium wilfordii Hook F ) treatment patient lupus nephritis . Open-labeled , randomize , prospective multi-center clinical trial . Observation period 24 week .</brief_summary>
	<brief_title>Efficacy Safety Tripterygium Wilfordii Patients With Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Age 1865 year inform consent SLE define meet 4 ACR classification criterion Biopsyproven active proliferative lupus glomerulonephritis ISN classification Class III IV Active renal disease Pregnant , lactate fertility requirement Serum creatinine &gt; 3 mg/dL Serum ALT AST &gt; 3 time upper limit normal Severe , progressive renal , hepatic , hematological , gastrointestinal , pulmonary , cardiovascular , neurological , endocrine cerebral disease Previous treat cyclophosphamide T2 . Not discontinue MMF , azathioprine , leflunomide , methotrexate , calcineurin inhibitor 1 month randomization . Active chronic infection , include HIV , HCV , HBV , tuberculosis Patient malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Tripterygium</keyword>
</DOC>